Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 33.3%High 2 · 66.7%

Bortezomib vs no bortezomib

Overall Survival ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma

Bortezomib probably leads to lower overall Survival ‐ Bortezomib versus no bortezomib (same background… compared with no bortezomib (moderate certainty).

1 finding from 1 review

Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
Odds Ratio 0.77 [0.65, 0.92]
4 studies · 1586 participants
Moderate

Bortezomib vs no bortezomib

Overall Survival ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma

Bortezomib leads to lower overall Survival ‐ Bortezomib versus no bortezomib (different… compared with no bortezomib (high certainty).

1 finding from 1 review

Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
Odds Ratio 0.76 [0.67, 0.88]
5 studies · 2532 participants
High

Bortezomib vs no bortezomib

Overall survival · All patients with a diagnosis of multiple myeloma

Bortezomib leads to lower overall Survival compared with no bortezomib (high certainty).

1 finding from 1 review

Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
Odds Ratio 0.77 [0.69, 0.86]
9 studies · 4118 participants
High